Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
暂无分享,去创建一个
L. Valenti | S. Fargion | G. Baselli | M. Maggioni | S. Gatti | A. Pietrelli | S. Badiali | V. Trunzo | P. Dongiovanni | M. Meroni | R. Rametta | G. A. Bassani | F. Facciotti
[1] E. Paschetta,et al. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis , 2017, JAMA internal medicine.
[2] G. Marchesini,et al. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[3] J. Trebicka,et al. Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression , 2017, Gut.
[4] D. Schuppan,et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal , 2017, Gut.
[5] Brad J. Wood,et al. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[6] G. Targher,et al. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[7] E. Bugianesi,et al. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease , 2016, PloS one.
[8] K. Nakao,et al. Lipotoxicity pathways intersect in hepatocytes: Endoplasmic reticulum stress, c‐Jun N‐terminal kinase‐1, and death receptors , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.
[9] Dermot F. Reilly,et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. , 2016, Gastroenterology.
[10] H. Yki-Järvinen,et al. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review , 2016, International journal of molecular sciences.
[11] O. Ilkayeva,et al. Integrated Regulation of Hepatic Lipid and Glucose Metabolism by Adipose Triacylglycerol Lipase and FoxO Proteins. , 2016, Cell reports.
[12] S. Bellentani,et al. A "systems medicine" approach to the study of non-alcoholic fatty liver disease. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[13] Luca Valenti,et al. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target? , 2016, Expert review of gastroenterology & hepatology.
[14] Ji Luo,et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis , 2016, Nature.
[15] E. Bjornsson,et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.
[16] S. Romeo,et al. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis , 2015, BioMed research international.
[17] Mary E Rinella,et al. Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.
[18] A. Burt,et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.
[19] Y. Kido,et al. Pathogenesis of Selective Insulin Resistance in Isolated Hepatocytes* , 2015, The Journal of Biological Chemistry.
[20] C. Trautwein,et al. Hepatic fibrosis: Concept to treatment. , 2015, Journal of hepatology.
[21] G. Alexander,et al. Selective insulin resistance in hepatocyte senescence. , 2015, Experimental cell research.
[22] K. Cusi,et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease , 2015, Hepatology.
[23] V. Ratziu,et al. Pharmacological agents for NASH , 2013, Nature Reviews Gastroenterology &Hepatology.
[24] A. Lonardo,et al. From NAFLD in clinical practice to answers from guidelines. , 2013, Journal of hepatology.
[25] L. N. Valenti,et al. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects , 2013, International Journal of Obesity.
[26] S. Friedman,et al. Mechanisms of hepatic fibrogenesis. , 2011, Best practice & research. Clinical gastroenterology.
[27] A. Dejean,et al. Highly specialized role of Forkhead box O transcription factors in the immune system. , 2011, Antioxidants & redox signaling.
[28] T. Libermann,et al. Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells , 2011, Hepatology.
[29] C. Wai,et al. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.
[30] L. N. Valenti,et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease , 2010, Gut.
[31] F. Marra,et al. Adipokines in liver diseases , 2009, Hepatology.
[32] S. Caldwell,et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.
[33] L. N. Valenti,et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.
[34] R. Green,et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet , 2008 .
[35] E. Van Obberghen,et al. Nuclear forkhead box O1 controls and integrates key signaling pathways in hepatocytes. , 2007, Endocrinology.
[36] D. Brenner,et al. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. , 2007, Gastroenterology.
[37] R. Goldin,et al. Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research , 2006, International journal of experimental pathology.
[38] Y. Baruch,et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. , 2005, Journal of hepatology.
[39] D. Accili,et al. Transgenic rescue of insulin receptor-deficient mice. , 2004, The Journal of clinical investigation.
[40] D. Accili,et al. FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation , 2004, Cell.
[41] D. Accili,et al. In Vivo Mutagenesis of the Insulin Receptor* , 2003, Journal of Biological Chemistry.
[42] R. Fisher,et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.
[43] D. Accili,et al. Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1 , 2002, Nature Genetics.
[44] Á. Valverde,et al. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. , 2011, Journal of hepatology.
[45] R. Witek,et al. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. , 2009, Gastroenterology.
[46] Mark D. Johnson,et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene , 1996, Nature Genetics.